MOH Q2 Adj. EPS $1.51 vs est. $1.39; Rev $10.87B; Premium Rev $10.24B vs est $10.794B; EBIT $145Mm VS EST $143.87mM; Medicaid MCR 92.7%; see
MOH Q2 Adj. EPS $1.51 vs est. $1.39; Rev $10.87B; Premium Rev $10.24B vs est $10.794B; EBIT $145Mm VS EST $143.87mM; Medicaid MCR 92.7%; sees FY Adj. EPS ≥$5.25 (incl. ~$1.50/shr FL Medicaid contract drag in Q4) vs est $5.156 and FY Premium Revs ~$42B vs est $44.355B; shares -7%
MOH Q2 Adj.
EPS $1.51 vs est. $1.39; Rev $10.87B; Premium Rev $10.24B vs est $10.794B; EBIT $145Mm VS EST $143.87mM; Medicaid MCR 92.7%; sees FY Adj.
EPS ≥$5.25 (incl. ~$1.50/shr FL Medicaid contract drag in Q4) vs est $5.156 and FY Premium Revs ~$42B vs est $44.355B; shares -7%